CA3121241A1 - Antagonistes d'hormone de croissance pegyles - Google Patents

Antagonistes d'hormone de croissance pegyles Download PDF

Info

Publication number
CA3121241A1
CA3121241A1 CA3121241A CA3121241A CA3121241A1 CA 3121241 A1 CA3121241 A1 CA 3121241A1 CA 3121241 A CA3121241 A CA 3121241A CA 3121241 A CA3121241 A CA 3121241A CA 3121241 A1 CA3121241 A1 CA 3121241A1
Authority
CA
Canada
Prior art keywords
growth hormone
human growth
polyethylene glycol
cysteine
hormone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121241A
Other languages
English (en)
Inventor
Richard S. Brody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Technologies Laboratories LLC
Original Assignee
Molecular Technologies Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/216,230 external-priority patent/US10874717B2/en
Application filed by Molecular Technologies Laboratories LLC filed Critical Molecular Technologies Laboratories LLC
Publication of CA3121241A1 publication Critical patent/CA3121241A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition qui est un antagoniste du récepteur de l'hormone de croissance humaine comprenant l'antagoniste du récepteur de l'hormone de croissance humaine G120K, un ou deux acides aminés de l'antagoniste du récepteur de l'hormone de croissance humaine G120K ayant été mutés en cystéine ; et une molécule de polyéthylène glycol conjuguée à chaque cystéine substituée dans le mutant de l'antagoniste du récepteur de l'hormone de croissance humaine G120K.
CA3121241A 2018-12-11 2019-12-10 Antagonistes d'hormone de croissance pegyles Pending CA3121241A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/216,230 US10874717B2 (en) 2015-07-07 2018-12-11 Pegylated growth hormone antagonists
US16/216,230 2018-12-11
PCT/US2019/065385 WO2020123450A1 (fr) 2018-12-11 2019-12-10 Antagonistes d'hormone de croissance pégylés

Publications (1)

Publication Number Publication Date
CA3121241A1 true CA3121241A1 (fr) 2020-06-18

Family

ID=71076634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121241A Pending CA3121241A1 (fr) 2018-12-11 2019-12-10 Antagonistes d'hormone de croissance pegyles

Country Status (4)

Country Link
EP (1) EP3893919A4 (fr)
JP (1) JP2022511951A (fr)
CA (1) CA3121241A1 (fr)
WO (1) WO2020123450A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
CN103690936A (zh) * 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
US20170007711A1 (en) 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists
WO2019211842A1 (fr) 2018-04-30 2019-11-07 Opko Biologics Ltd. Antagonistes de l'hormone de croissance humaine à action prolongée et leurs procédés de production

Also Published As

Publication number Publication date
JP2022511951A (ja) 2022-02-01
EP3893919A4 (fr) 2022-11-30
EP3893919A1 (fr) 2021-10-20
WO2020123450A1 (fr) 2020-06-18

Similar Documents

Publication Publication Date Title
US20170007711A1 (en) Pegylated growth hormone antagonists
JP6023703B2 (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
AU2018287145B2 (en) Modified L-asparaginase
US10874717B2 (en) Pegylated growth hormone antagonists
US10174302B1 (en) Modified L-asparaginase
US11578427B2 (en) Designed ankyrin repeat domains with altered surface residues
Wu et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
EP3418383A1 (fr) L-asparaginase modifié
CN107207623B (zh) Fc融合高亲和力IgE受体α链
US20160024179A1 (en) Modified fc fusion proteins
Qiu et al. Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action
AU2017357327B2 (en) Pegylated endostatin analogue and application thereof
CA2710841A1 (fr) G-csf modifie par du polyethylene de type y, procede de fabrication et utilisation associes
CN116102621A (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
EP3154563B1 (fr) Nouveau polypeptide
CN101553501A (zh) Il-21变种
CA3121241A1 (fr) Antagonistes d'hormone de croissance pegyles
CN101585864A (zh) 柱层析粒细胞集落刺激因子氮端定点偶联方法及其产物
CN114751962B (zh) 订书肽、其制备方法及其制药用途
US20100249029A1 (en) Peptides with high affinity for the prolactin receptor
CA3141128A1 (fr) Antagonistes therapeutiques d'hormone de croissance pegylee
Nakamura et al. C-terminal cysteine PEGylation of adalimumab Fab with an engineered interchain SS bond
CN112442496B (zh) 精氨酸脱亚胺酶突变体及其应用
CN114763369A (zh) 脂肪肽链及Fab-脂肪链偶联物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526

EEER Examination request

Effective date: 20210526